TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial

Lancet Neurology

Volumn 5, Issue 12, 2006, Pages 1013-1020

  Olanow, C Warren ^a   Schapira, Anthony HV ^b   LeWitt, Peter A ^c   Kieburtz, Karl ^d   Sauer, Dirk ^e   Olivieri, Gianfranco ^e   Pohlmann, Harald ^e   Hubble, Jean ^e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPROTECTIVE AGENT; PLACEBO; THC 346; UNCLASSIFIED DRUG;

ADULT; AGED; AMNESIA; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; NAUSEA; NEUROPROTECTION; PAIN; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; OXEPINS; PARKINSON DISEASE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33750719088     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(06)70602-0     Document Type: Article

References (55)

1. Lang A., and Lozano A. Parkinson's disease. N Engl J Med 339 (1998) 1044-1053
2. Forno L. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55 (1996) 259-272
3. Olanow C., Watts R., and Koller W. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 56 suppl 5 (2001) 1-88
4. Olanow C. The scientific basis for the current treatment of Parkinson's disease. Ann Rev Med 55 (2004) 41-60
5. Braak H., Del Tredici K., Rub U., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2003) 197-211
6. The Deep Brain Stimulation for PD study group. Deep brain stimulation of the subthalamic nucleus or globus pallidus pars interna in Parkinson's disease. New Eng J Med 345 (2001) 956-963
7. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328 (1993) 176-183
8. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson's disease progression. JAMA 287 (2002) 1653-1661
9. Whone A., Watts R., Stoessl A., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54 (2003) 93-101
10. Shults C., Oakes D., Kieburtz K., et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59 (2002) 1541-1550
11. Olanow C., and Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord 20 suppl 11 (2005) S3-S10
12. Schapira A., and Olanow C. Neuroprotection in Parkinson's disease: myths, mysteries, and misconceptions. JAMA 291 (2004) 358-364
13. Boulton A. Symptomatic and neuroprotective properties of the aliphatic propargylamines. Mech Ageing Dev 111 (1999) 201-209
14. Carlile G., Chalmers-Redman R., Tatton N., et al. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol 57 (2000) 2-12
15. Tatton W., Chalmers-Redman R., Ju W., et al. Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 301 (2002) 753-764
16. Kragten E., Lalande I., Zimmermann K., et al. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J Biol Chem 273 (1998) 5821-5828
17. Waldmeier P., Spooren W., and Hengerer B. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 362 (2000) 526-537
18. Matarredona E., Meyer M., Seiler R., and Widmer H. CGP 3466 increases survival of cultured fetal dopaminergic neurons. Restor Neurol Neurosci 21 (2003) 29-37
19. Waldmeier P., Boulton A., Cools A., et al. Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural Transm Suppl 60 (2000) 197-214
20. Andringa G., van Oosten R., Unger W., et al. Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra. Eur J Neurosci 12 (2000) 3033-3043
21. Andringa G., Eshuis S., and Perentes E. TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates. Neurobiol Dis 14 (2003) 205-217
22. Ishitani R., Sunaga K., Hirano A., et al. Evidence that glyceraldehyde-3-phosphate-dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture. J Neurochem 66 (1996) 928-935
23. Hoehn M., and Yahr M. Parkinsonism: onset, progression, and mortality. Neurology 17 (1967) 427-442
24. Fahn S., Elton R., and UPDRS Development Committee. The unified Parkinson's disease rating scale. In: Fahn S., Marsden C., Calne D., and Goldstein M. (Eds). Recent developments in Parkinson's disease vol 2 (1987), Macmillan Healthcare Information, Florham Park, NJ 153-163
25. Goetz C., LeWitt P., and Weidenman M. Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program. Mov Disord 18 (2003) 1455-1458
26. Goetz C., and Stebbins G. Assuring interrater reliability for the UPDRS motor section: utility of the UPDRS teaching tape. Mov Disord 19 (2004) 1453-1456
27. Jenkinson C., Peto V., Fitzpatrick R., et al. Self reported functioning and well-being in patients with Parkinson's disease: comparison of short form health survey (SF36) and the Parkinson diseae questionnaire (PDQ39). Age Ageing 24 (1995) 505-509
28. Chuang D., and Ishitani R. A role for GAPDH in apoptosis and neurodegeneration. Nat Med 2 (1996) 609-610
29. Sawa A., Khan A., Hester L., and Snyder S. Glyderaldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and non-neuronal cell death. Proc Natl Acad Sci USA 94 (1997) 11669-11674
30. Ishitani R., Kimura M., Sunaga K., Katsube N., Tanaka M., and Chuang D. An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. J Pharmacol Exp Ther 278 (1996) 447-454
31. Hirsch E., Hunot S., Faucheux B., et al. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov Disord 14 (1999) 383-385
32. Tatton N. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 166 (2000) 29-43
33. Hartmann A., Mouatt-Prigent A., Vila M., et al. Increased expression and redistribution of the antiapoptotic molecule Bcl-xL in Parkinson's disease. Neurobiol Dis 10 (2002) 28-32
34. Olanow C., Mytilineou C., and Tatton W. Status of Selegiline as a neuroprotective agent in Parkinson's disease. Mov Disord 13 (1998) 55-58
35. Tatton W., Chalmers-Redman R., and Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 110 (2003) 509-515
36. Olanow C. Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. Neurology 66 10 suppl 4 (2006) S69-S79
37. Olanow C., and Calne D. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms?. Neurology 42 (1992) 13-26
38. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson's disease (the TEMPO study). Arch Neurol 59 (2002) 1937-1943
39. Lang A., Gill S., Patel N., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59 (2006) 459-466
40. Beal M. Experimental models of Parkinson's disease. Nat Rev Neurosci 2 (2001) 325-334
41. McNaught K., Belizaire R., Isacson O., Jenner P., and Olanow C. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 179 (2003) 38-46
42. McNaught K., Perl D., Brownell A.-L., and Olanow C. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56 (2004) 149-162
43. McNaught K., and Olanow C. Proteasome inhibitor-induced model of Parkinson's disease. Ann Neurol 60 (2006) 243-247
44. Zeng B.-Y., Bukhatwa S., Hikima A., et al. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann Neurol 60 (2006) 248-252
45. Schapira A., Cleeter M., Muddle J., et al. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol 60 (2006) 253-255
46. Manning-Bog A., Reaney S., Chou V., et al. Lack of nigrostriatal pathology in a rat model of proteasomal inhibition. Ann Neurol 60 (2006) 256-260
47. Bove J., Zhou C., Jackson-Lewis V., et al. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol 60 (2006) 260-264
48. Kordower J., Kanaan N., Chu Y., et al. Failure of proteasome inhibitor administration to provide a model of parkinson's disease in rats and monkeys. Ann Neurol 60 (2006) 264-268
49. Schapira A., and Olanow C. Neuroprotection in Parkinson's disease: myths, mysteries, and misconceptions. JAMA 291 (2004) 358-364
50. Olanow C., Kieburtz K., Stern M., et al. Double-blind, controlled study of entacapone in levodopa-treated stable Parkinson's disease patients. Arch Neurol 61 (2004) 1563-1568
51. Schapira A., and Obeso J. Timing of treatment initiation in Parkinson's diease: a need for reappraisal?. Ann Neurol 59 (2006) 559-652
52. Olanow C., Schapira A., and Agid Y. Causes of cell death and prospects for neuroprotection in Parkinson's disease. Ann Neurol 53 suppl 3 (2002) 1-170
53. Moore D., West A., Dawson V., and Dawson T. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28 (2005) 57-87
54. Ravina B., Fagan S., Hart R., et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60 (2003) 1234-1240
55. Waldmeier P., Bozyczko-Coyne D., Williams M., and Vaught J. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol (2006). published online Aug 8. DOI:10.1016/j.bcp.2006.06.031